On Thursday, 1 September, the Committee for Medicinal Products for Human Use (CHMP) in the European Medicines Agency (EMA) issued two recommendations in favour of conditional marketing authorisation for two Covid-19 vaccines that have been adapted to the Omicron variant.
These vaccines are the Comirnaty vaccine developed by pharmaceutical companies Pfizer and BioNtech and the Spikevax vaccine developed by Moderna. These two messenger RNA vaccines have been adapted in order to provide protection against the original SARS-CoV-2 virus as well as the worrying BA.1 subvariant. Both vaccines are for people who are 12 years of age and older and have also already completed a primary vaccination regimen for SARS-CoV-2.
In addition, the EMA previously announced on 30 August that it had started the evaluation process for the Comirnaty Covid-19 vaccine developed by Pfizer and BioNtech that has been adapted not only to the original SARS-CoV-2 variant but also the BA.4 and BA.5 subvariants (see EUROPE 13001/22). (Original version in French by Emilie Vanderhulst)